查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1738671

流感病毒（H1N1）疫苗市场规模依疫苗类型、技术、年龄层、区域范围和预测划分：

Global Influenza Virus Vaccine (H1N1) Market Size By Vaccine Type, By Technology, By Age Group, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

流感病毒（H1N1）疫苗市场规模及预测

2024 年流感病毒 (H1N1) 疫苗市场规模价值为 38 亿美元，预计到 2032 年将达到 56.2 亿美元，预测期内（2026-2032 年）的复合年增长率为 5.52%。

推动全球流感病毒（H1N1）疫苗市场发展的因素

流感病毒 (H1N1) 疫苗市场的市场驱动因素可能受到多种因素的影响，其中包括：

  • 流感病例数上升：全球流感发生率上升是推动H1N1疫苗市场成长的主要因素。季节性流行病和大流行病导致的高发病率和高死亡率，推动了对有效疫苗的需求。
  • 政府疫苗宣传活动和计画：全球各地政府都在进行疫苗宣传活动，以控制和避免流感疫情爆发。这些措施推动了市场需求，包括免费或高额补贴的疫苗接种项目以及公众意识宣传活动。
  • 免疫技术的进步：疫苗研发的进步，例如重组疫苗和细胞製造技术，正在提高疫苗生产的有效性和效率。这些发展正在推动疫苗覆盖率和投资的增加。
  • 教育和公众意识：随着人们越来越意识到疫苗接种的好处和流感的风险，接种疫苗的人数也在增加。这需要政府和医疗机构的教育投入。
  • 人口老化：随着全球老年人口的增长，对 H1N1併发症的需求也随之增加，老年人成为流感疫苗接种宣传活动的主要目标群体。
  • 医疗基础建设：更完善的医疗基础设施，尤其是在开发中国家，将使疫苗的分发和管理更有效率。医疗服务的普及和医疗设施的改善将有助于市场扩张。
  • 病毒的季节性变异：流感病毒的变异性使得疫苗接种必须每年更新，以确保对最新疫苗的需求稳定。季节性流感病毒的流行推动了復发性疫苗的分发和研发。

限制全球甲型H1N1流感疫苗市场的因素

多种因素可能对甲型H1N1流感疫苗市场造成限制和挑战，包括：

  • 生产成本高：流感疫苗，尤其是H1N1流感疫苗，研发和生产成本高。这些成本包括临床研究、生产製造、品管、研发等。高昂的生产成本可能会限制疫苗的可近性和可负担性，尤其是在低收入社区。
  • 严格的监管要求：疫苗核准流程漫长而艰鉅。在获准用于公众使用之前，疫苗必须符合食品药物管理局(FDA) 和欧洲药品管理局 (EMA) 等监管机构制定的严格标准和要求。这可能会延迟新疫苗的上市。
  • 疫苗犹豫：低疫苗接种率可归因于公众对疫苗有效性和安全性的不信任和错误讯息。许多因素，包括文化观念、社群媒体传播的错误讯息以及既往疫苗接种经历，都会影响疫苗犹豫。
  • 供应链挑战：由于复杂的製造流程、复杂的低温运输物流、分销问题等，维持稳定的疫苗供应具有挑战性。供应链的任何中断都可能影响疫苗供应的时间表。
  • 有效性有限：流感疫苗，尤其是大流行性流感疫苗的有效性，可能因疫苗株与流行病毒株的匹配程度而每年都有所不同。疫苗有效性的波动可能会影响公众信任度和疫苗接种率。
  • 智慧财产权和专利问题：专利和智慧财产权可能会阻碍新市场的进入，抑制竞争和创新，并影响疫苗的取得和成本。
  • 资金限制：疫苗开发、研究和分发资金不足可能会阻碍市场扩张。这在资源匮乏的开发中国家尤其成问题。
  • 安全性和副作用担忧：疫苗通常是安全的，但关于副作用的报告可能会影响大众的接受度和认知。对疫苗安全性的担忧可能会导致疫苗接种率下降，并阻碍市场扩张。
  • 政治和经济因素：公共卫生宣传活动、疫苗分发和疫苗生产都可能受到政治不稳定或景气衰退的不利影响。预算削减和优先顺序调整可能会导致免疫接种计画的资金和支持减少。
  • 技术限制：疫苗製造技术不断发展，但技术限制可能会对实现更快、更有效的免疫造成障碍。

目录

第一章 引言

  • 市场定义
  • 市场区隔
  • 调查方法

第二章执行摘要

  • 主要发现
  • 市场概览
  • 市集亮点

第三章市场概述

  • 市场规模和成长潜力
  • 市场趋势
  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析

4. 甲型H1N1流感疫苗市场（依疫苗类型）

  • 灭活疫苗
  • 活病毒疫苗

5. 流感病毒（H1N1）疫苗市场（依技术）

  • 基于鸡蛋的技术
  • 基于细胞的技术
  • 重组技术

6. 甲型H1N1流感疫苗市场（依年龄层）

  • 孩子们
  • 成人
  • 老年人

第七章区域分析

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 欧洲
  • 英国
  • 德国
  • 法国
  • 义大利
  • 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 拉丁美洲
  • 巴西
  • 阿根廷
  • 智利
  • 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国

第八章市场动态

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • COVID-19 市场影响

第九章 竞争态势

  • 主要企业
  • 市场占有率分析

第十章 公司简介

  • Butantan Institute
  • Denka Seiken Co Ltd
  • Green Cross Corp
  • Baxter International Inc.
  • CSL
  • Glaxosmithkline PLC
  • Hualan Biological Engineering Inc.
  • Novartis
  • Sinovac Biotech
  • Sanofi Pasteur

第十一章 市场展望与机会

  • 新兴技术
  • 未来市场趋势
  • 投资机会

第十二章 附录

  • 简称列表
  • 来源和参考文献
简介目录
Product Code: 35803

Influenza Virus Vaccine (H1N1) Market Size And Forecast

Influenza Virus Vaccine (H1N1) Market size was valued at USD 3.8 Billion in 2024 and is projected to reach USD 5.62 Billion by 2032, growing at a CAGR of 5.52% during the forecast period 2026-2032.

Global Influenza Virus Vaccine (H1N1) Market Drivers

The market drivers for the Influenza Virus Vaccine (H1N1) Market can be influenced by various factors. These may include:

  • A Rise in the Number of Influenza Cases: The global increase in influenza incidence is a major factor propelling the market for the H1N1 vaccination. High rates of morbidity and mortality brought on by seasonal outbreaks and pandemics raise the need for efficacious vaccinations.
  • Governmental Campaigns and Vaccine Programs: Worldwide, immunization campaigns are being carried out by governments in an effort to contain and avoid influenza outbreaks. These measures, which increase market demand, include immunization programs that are either free or heavily subsidized and public awareness campaigns.
  • Progress in Immunization Technology: The effectiveness and efficiency of vaccine manufacture have increased thanks to advancements in vaccine development, including recombinant vaccines and cell-based manufacturing techniques. These developments foster greater adoption rates and draw in more investments.
  • Education and Public Awareness: As people become more aware of the advantages of vaccination and the dangers of influenza, the number of people being vaccinated has increased. Government and healthcare groups' educational initiatives are vital to this.
  • Population Aging: The need for H1N1 vaccinations is driven by the growing senior population worldwide, who are more vulnerable to influenza complications. One important target group for influenza vaccination campaigns is older persons.
  • Development of Healthcare Infrastructure: Enhancements in the infrastructure of healthcare, especially in developing nations, enable more efficient distribution and administration of vaccinations. Access to medical services and improved healthcare facilities facilitate market expansion.
  • The Virus's Seasonal Variability: Annual vaccination updates are necessary due to the influenza virus's changing nature, which guarantees a steady demand for the newest vaccinations. The dissemination and development of recurrent vaccines are driven by seasonal flu viruses.

Global Influenza Virus Vaccine (H1N1) Market Restraints

Several factors can act as restraints or challenges for the Influenza Virus Vaccine (H1N1) Market. These may include:

  • High Production Costs: Developing and manufacturing influenza vaccines, especially those for H1N1, is expensive. These expenses cover clinical studies, manufacturing, quality control, and research & development. Particularly in low-income areas, high production costs may restrict the accessibility and affordability of vaccines.
  • Tight Regulatory Requirements: The approval process for vaccines is a laborious and time-consuming process. Before a vaccine is licensed for use in the general population, it must comply with strict standards and requirements set by regulatory authorities like the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This may cause a delay in the release of new vaccines.
  • Vaccine Hesitancy: Reduced vaccination rates may result from public mistrust and false information regarding the efficacy and safety of vaccines. A number of factors, including as cultural views, false information disseminated via social media, and prior vaccination experiences, all have an impact on vaccine hesitancy.
  • Supply Chain Difficulties: Keeping a steady supply of vaccinations in place can be difficult because of things like complicated manufacturing processes, complicated cold chain logistics, and problems with distribution. Any interruption to the supply chain may have an impact on when vaccines are available on time.
  • Limited Efficacy: Depending on how well the vaccine strains match the strains of the virus that is circulating, the efficacy of influenza vaccinations, particularly the H1N1, can change from year to year. Public trust and vaccination uptake may be impacted by variations in vaccine efficacy.
  • Intellectual Property and Patent Issues: Patents and intellectual property rights have the potential to impede competition and innovation by erecting obstacles in the way of new market entrants. This may also have an impact on vaccine accessibility and cost.
  • Financial Restraints: Inadequate funds for vaccine development, research, and distribution may prevent the market from expanding. This is especially problematic in developing nations with constrained financial resources.
  • Safety and Adverse Effects Concerns: Vaccines are typically safe, but public acceptance and perception may be impacted by stories of negative effects. Fears regarding the safety of vaccines may cause vaccination rates to decline and hinder market expansion.
  • Political and Economic Factors: Public health campaigns, vaccine distribution, and vaccine manufacture can all be adversely affected by political unrest and economic downturns. Programs for immunization may receive less money and support as a result of budget cuts and rearranged priorities.
  • Technological Restrictions: Vaccine production technology is continuously developing. But there may be obstacles in the way of creating vaccinations that are both faster to produce and more effective due to existing technological restrictions.

Global Influenza Virus Vaccine (H1N1) Market Segmentation Analysis

The Global Influenza Virus Vaccine (H1N1) Market is Segmented on the basis of Vaccine Type, Technology, Age Group, and Geography.

Influenza Virus Vaccine (H1N1) Market, By Vaccine Type

  • Inactivated Vaccines: These vaccines contain killed viruses and are typically administered via injection.
  • Live Attenuated Vaccines: These contain weakened live viruses and are usually administered through nasal sprays.

Influenza Virus Vaccine (H1N1) Market, By Technology

  • Egg-Based Technology: Traditional method involving the growth of the virus in chicken eggs.
  • Cell-Based Technology: Uses cultured mammalian cells for virus growth.
  • Recombinant Technology: Involves the use of recombinant DNA technology to produce vaccines.

Influenza Virus Vaccine (H1N1) Market, By Age Group

  • Pediatric: Vaccines specifically formulated for children.
  • Adults: Standard doses for the general adult population.
  • Elderly: High-dose or adjuvanted vaccines for individuals over 65 years.
  • Influenza Virus Vaccine (H1N1) Market, Geography
  • North America: Market conditions and demand in the United States, Canada, and Mexico.
  • Europe: Analysis of the Influenza Virus Vaccine (H1N1) Market in European countries.
  • Asia-Pacific: Focusing on countries like China, India, Japan, South Korea, and others.
  • Middle East and Africa: Examining market dynamics in the Middle East and African regions.
  • Latin America: Covering market trends and developments in countries across Latin America.

Key Players

  • Butantan Institute
  • Denka Seiken Co Ltd
  • Green Cross Corp
  • Baxter International Inc.
  • CSL
  • Glaxosmithkline PLC
  • Hualan Biological Engineering Inc.
  • Novartis
  • Sinovac Biotech
  • Sanofi Pasteur

TABLE OF CONTENTS

1. Introduction

  • Market Definition
  • Market Segmentation
  • Research Methodology

2. Executive Summary

  • Key Findings
  • Market Overview
  • Market Highlights

3. Market Overview

  • Market Size and Growth Potential
  • Market Trends
  • Market Drivers
  • Market Restraints
  • Market Opportunities
  • Porter's Five Forces Analysis

4. Influenza Virus Vaccine (H1N1) Market, By Vaccine Type

  • Inactivated Vaccines
  • Live Attenuated Vaccines

5. Influenza Virus Vaccine (H1N1) Market, By Technology

  • Egg-Based Technology
  • Cell-Based Technology
  • Recombinant Technology

6. Influenza Virus Vaccine (H1N1) Market, By Age Group

  • Pediatric
  • Adults
  • Elderly

7. Regional Analysis

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • Latin America
  • Brazil
  • Argentina
  • Chile
  • Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

8. Market Dynamics

  • Market Drivers
  • Market Restraints
  • Market Opportunities
  • Impact of COVID-19 on the Market

9. Competitive Landscape

  • Key Players
  • Market Share Analysis

10. Company Profiles

  • Butantan Institute
  • Denka Seiken Co Ltd
  • Green Cross Corp
  • Baxter International Inc.
  • CSL
  • Glaxosmithkline PLC
  • Hualan Biological Engineering Inc.
  • Novartis
  • Sinovac Biotech
  • Sanofi Pasteur

11. Market Outlook and Opportunities

  • Emerging Technologies
  • Future Market Trends
  • Investment Opportunities

12. Appendix

  • List of Abbreviations
  • Sources and References